Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NH Stock Summary
Top 10 Correlated ETFs
NH
In the News

NantHealth, Inc. (NH) Q3 2022 Earnings Call Transcript
NantHealth, Inc. (NASDAQ:NH ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Ron Louks - Chief Operating Officer Bob Petrou - Chief Financial Officer Conference Call Participants Robert Jaffe Welcome everyone and thank you for joining us today to discuss NantHealth's 2022 Third Quarter Financial Results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

NantHealth to Report 2022 Third-Quarter Financial Results and Host Conference Call on Thursday, November 3
MORRISVILLE, N.C.

NantHealth, Inc. (NH) Management on Q2 2022 Results - Earnings Call Transcript
NantHealth, Inc. (NASDAQ:NH ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Ron Louks - Chief Operating Officer Bob Petrou - Chief Financial Officer Robert Jaffe Welcome, everyone, and thank you for joining us today to discuss NantHealth's 2022 second quarter financial results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

NantHealth's (NH) Management on Q1 2022 Results - Earnings Call Transcript
NantHealth, Inc. (NASDAQ:NH ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Robert Jaffe – Investor Relations Ron Louks – Chief Operating Officer Bob Petrou – Chief Financial Officer Conference Call Participants Robert Jaffe Welcome, everyone, and thank you for joining us today to discuss NantHealth's 2022 First Quarter Financial Results. On the call today are Ron Louks, Chief Operating Officer; and Bob Petrou, our Chief Financial Officer.

NantHealth, Inc. (NH) Q4 2021 Results - Earnings Call Transcript
NantHealth, Inc. (NH) Q4 2021 Results - Earnings Call Transcript

NantHealth, Inc. (NH) Reports Q4 Loss, Tops Revenue Estimates
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -11.11% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NantHealth, Inc. (NH) Reports Q3 Loss, Misses Revenue Estimates
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -25.00% and -18.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NantHealth's Chief Medical Officer to Educate on Advancing Equity in Cancer Care at the Oncology Clinical Pathways Congress 2021
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that Dr. Tiffany Avery, Chief Medical Officer, was selected to present a continuing education session at the Oncology Clinical Pathways Congress 2021. Dr. Avery's session, titled Utilizing Pathways to Advance Equity in Cancer Care, will take place virtually on Friday, October 1, 2021, and cover how clinical p

NantHealth, Inc. (NH) Management on Q2 2021 Results - Earnings Call Transcript
NantHealth, Inc. (NH) Management on Q2 2021 Results - Earnings Call Transcript

NantHealth, Inc. (NH) Reports Q2 Loss, Lags Revenue Estimates
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 20.00% and -5.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NH Financial details
NH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 11.14 | 12.29 | 13.04 | 9.89 | 8.23 | |
Net income per share | -22.51 | -26.4 | -8.53 | -7.63 | -7.66 | |
Operating cash flow per share | -10.43 | -4.07 | -1.19 | -2.28 | -3.64 | |
Free cash flow per share | -12.18 | -5.52 | -1.82 | -3.05 | -4.31 | |
Cash per share | 7.92 | 2.52 | 0.71 | 3.08 | 3.82 | |
Book value per share | 24.84 | 0.39 | -7.77 | -15.11 | -21.29 | |
Tangible book value per share | 1.19 | -24.43 | -30.57 | -36.23 | -39.34 | |
Share holders equity per share | 24.84 | 0.39 | -7.77 | -15.11 | -21.29 | |
Interest debt per share | 27.19 | 29.9 | 30.51 | 2.63 | 35.62 | |
Market cap | 356.05M | 59.41M | 113.66M | 358.38M | 120.43M | |
Enterprise value | 489.85M | 241.58M | 314.84M | 335.87M | 347.91M | |
P/E ratio | -2.03 | -0.31 | -1.81 | -6.35 | -2.07 | |
Price to sales ratio | 4.11 | 0.66 | 1.18 | 4.9 | 1.92 | |
POCF ratio | -4.39 | -2 | -12.97 | -21.26 | -4.35 | |
PFCF ratio | -3.76 | -1.48 | -8.51 | -15.91 | -3.67 | |
P/B Ratio | 1.84 | 20.99 | -1.99 | -3.21 | -0.74 | |
PTB ratio | 1.84 | 20.99 | -1.99 | -3.21 | -0.74 | |
EV to sales | 5.65 | 2.7 | 3.28 | 4.59 | 5.55 | |
Enterprise value over EBITDA | -3.68 | -1.55 | -14.01 | -16.77 | -12.44 | |
EV to operating cash flow | -6.04 | -8.15 | -35.92 | -19.93 | -12.56 | |
EV to free cash flow | -5.17 | -6.01 | -23.57 | -14.91 | -10.62 | |
Earnings yield | -0.49 | -3.23 | -0.55 | -0.16 | -0.48 | |
Free cash flow yield | -0.27 | -0.68 | -0.12 | -0.06 | -0.27 | |
Debt to equity | 1.32 | 100.14 | -5.66 | -2.79 | -2.22 | |
Debt to assets | 0.57 | 0.99 | 1.21 | 1.64 | 1.82 | |
Net debt to EBITDA | -1 | -1.17 | -8.95 | 1.12 | -8.14 | |
Current ratio | 2.28 | 1.08 | 0.66 | 0.25 | 1.41 | |
Interest coverage | -4.2 | -2.96 | -1.71 | -1.37 | -2.82 | |
Income quality | 0.46 | 0.15 | 0.14 | 0.3 | 0.48 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.87 | 0.79 | 0.64 | 0.66 | 0 | |
Research and developement to revenue | 0.39 | 0.23 | 0.2 | 0.24 | 0.31 | |
Intangibles to total assets | 0.41 | 0.63 | 0.63 | 0.77 | 0.69 | |
Capex to operating cash flow | 0.17 | 0.36 | 0.52 | 0.34 | 0.18 | |
Capex to revenue | -0.16 | -0.12 | -0.05 | -0.08 | -0.08 | |
Capex to depreciation | -0.49 | -0.47 | -0.21 | -0.34 | -0.32 | |
Stock based compensation to revenue | 0.05 | 0.06 | 0.03 | 0.04 | 0.06 | |
Graham number | 112.17 | 15.2 | 38.61 | 50.94 | 60.55 | |
ROIC | -0.21 | -0.2 | -0.12 | -0.19 | -0.3 | |
Return on tangible assets | -0.66 | -1.82 | -0.64 | -1.29 | -0.96 | |
Graham Net | -23.74 | -34.73 | -40.33 | -38.72 | -42.84 | |
Working capital | 46.03M | 2.91M | -19.59M | -94.16M | 11.47M | |
Tangible asset value | 9.25M | -177.8M | -224.91M | -267.99M | -299.36M | |
Net current asset value | -174M | -244.06M | -285.71M | -281.09M | -320.41M | |
Invested capital | 1.01 | 70.81 | -3.61 | 0 | -1.58 | |
Average receivables | 13.35M | 14.18M | 22.33M | 15.82M | 4.79M | |
Average payables | 4.94M | 2.41M | 2.8M | 4.54M | 4.16M | |
Average inventory | 1.53M | 667.5K | 647K | 399K | 0 | |
Days sales outstanding | 50.85 | 66.47 | 107.9 | 16.33 | 36.8 | |
Days payables outstanding | 27.81 | 13.6 | 37.53 | 32.56 | 42.06 | |
Days of inventory on hand | 7.38 | 4.09 | 7.58 | 0 | 0 | |
Receivables turnover | 7.18 | 5.49 | 3.38 | 22.36 | 9.92 | |
Payables turnover | 13.12 | 26.83 | 9.72 | 11.21 | 8.68 | |
Inventory turnover | 49.49 | 89.25 | 48.15 | 0 | 0 | |
ROE | -0.91 | -67.87 | 1.1 | 0.5 | 0.36 | |
Capex per share | -1.75 | -1.45 | -0.62 | -0.77 | -0.67 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 1.86 | 2.08 | 2.13 | 2.14 | 2.16 | |
Net income per share | -1.41 | -2.17 | -2.07 | -1.62 | -1.77 | |
Operating cash flow per share | -0.74 | -0.69 | -1.43 | -1.19 | -0.65 | |
Free cash flow per share | -0.96 | -0.81 | -1.59 | -1.4 | -0.82 | |
Cash per share | 5.92 | 3.78 | 2.09 | 0.74 | 0.08 | |
Book value per share | -19.11 | -21.04 | -22.93 | -24.42 | -26.11 | |
Tangible book value per share | -37.28 | -38.89 | -40.48 | -41.67 | -43.08 | |
Share holders equity per share | -19.11 | -21.04 | -22.93 | -24.42 | -26.11 | |
Interest debt per share | 35.51 | 33.79 | 33.85 | 33.78 | 33.86 | |
Market cap | 185.54M | 121.81M | 87.06M | 48.25M | 28.46M | |
Enterprise value | 409.29M | 349.3M | 328.23M | 299.3M | 285.18M | |
P/E ratio | -4.28 | -1.82 | -1.36 | -0.96 | -0.52 | |
Price to sales ratio | 12.97 | 7.6 | 5.32 | 2.92 | 1.71 | |
POCF ratio | -32.55 | -22.97 | -7.88 | -5.28 | -5.66 | |
PFCF ratio | -25.06 | -19.43 | -7.11 | -4.47 | -4.5 | |
P/B Ratio | -1.26 | -0.75 | -0.49 | -0.26 | -0.14 | |
PTB ratio | -1.26 | -0.75 | -0.49 | -0.26 | -0.14 | |
EV to sales | 28.61 | 21.79 | 20.05 | 18.14 | 17.15 | |
Enterprise value over EBITDA | -122.1 | -38.94 | -38.76 | -57.71 | -46.44 | |
EV to operating cash flow | -71.8 | -65.86 | -29.71 | -32.73 | -56.76 | |
EV to free cash flow | -55.27 | -55.72 | -26.79 | -27.7 | -45.13 | |
Earnings yield | -0.06 | -0.14 | -0.18 | -0.26 | -0.48 | |
Free cash flow yield | -0.04 | -0.05 | -0.14 | -0.22 | -0.22 | |
Debt to equity | -2.48 | -2.22 | -2.03 | -1.89 | -1.8 | |
Debt to assets | 1.68 | 1.82 | 1.97 | 2.13 | 2.25 | |
Net debt to EBITDA | -66.75 | -25.36 | -28.48 | -48.41 | -41.8 | |
Current ratio | 1.64 | 1.41 | 1.04 | 0.63 | 0.36 | |
Interest coverage | -3.1 | -3.35 | -3.62 | -3.38 | -4.03 | |
Income quality | 0.53 | 0.32 | 0.69 | 0.73 | 0.37 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.32 | 0.32 | 0.35 | 0.36 | 0.38 | |
Intangibles to total assets | 0.64 | 0.69 | 0.74 | 0.8 | 0.81 | |
Capex to operating cash flow | 0.3 | 0.18 | 0.11 | 0.18 | 0.26 | |
Capex to revenue | -0.12 | -0.06 | -0.07 | -0.1 | -0.08 | |
Capex to depreciation | -0.44 | -0.23 | -0.3 | -0.43 | -0.32 | |
Stock based compensation to revenue | 0.06 | 0.08 | 0.08 | 0.08 | 0.05 | |
Graham number | 24.63 | 32.06 | 32.69 | 29.87 | 32.27 | |
ROIC | -0.09 | -0.09 | -0.09 | -0.08 | -0.09 | |
Return on tangible assets | -0.14 | -0.28 | -0.34 | -0.37 | -0.45 | |
Graham Net | -40.89 | -42.35 | -43.86 | -44.8 | -46.24 | |
Working capital | 22.23M | 11.47M | 1.12M | -8.73M | -21.44M | |
Tangible asset value | -286.4M | -299.36M | -311.74M | -321.01M | -331.84M | |
Net current asset value | -307.36M | -320.41M | -331.87M | -340.12M | -349.93M | |
Invested capital | -1.83 | -1.58 | -1.46 | -1.36 | -1.28 | |
Average receivables | 5.68M | 6.17M | 5.92M | 5.53M | 6.28M | |
Average payables | 2.2M | 2.64M | 4.25M | 5.07M | 5.53M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 37.87 | 35.46 | 30.4 | 30.14 | 38.01 | |
Days payables outstanding | 27.47 | 41.63 | 66.29 | 59.38 | 80.75 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.38 | 2.54 | 2.96 | 2.99 | 2.37 | |
Payables turnover | 3.28 | 2.16 | 1.36 | 1.52 | 1.11 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.07 | 0.1 | 0.09 | 0.07 | 0.07 | |
Capex per share | -0.22 | -0.13 | -0.16 | -0.22 | -0.17 |
NH Frequently Asked Questions
What is NantHealth, Inc. stock symbol ?
NantHealth, Inc. is a US stock , located in Morrisville of Nc and trading under the symbol NH
What is NantHealth, Inc. stock quote today ?
NantHealth, Inc. stock price is $2.26 today.
Is NantHealth, Inc. stock public?
Yes, NantHealth, Inc. is a publicly traded company.